Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
Interleukin-2-(IL-2)-activated lymphocytes have been shown to kill a variety of continuously cultured allogeneic (nonself), natural killer cell-sensitive and resistant cell lines, and some autologous (self) tumor cells. Lymphokine-activated killer (LAK) cytotoxicity of autologous head and neck squamous cell carcinoma (HNSCC) cells has not been previously demonstrated, and efforts to demonstrate this have been hampered by the lack of a reliable and reproducible method of obtaining satisfactory tumor targets. In this study, fresh tumor cells were enzymatically dissociated, enriched by adherence to plastic, and used in a 3-hour chromium-51 cytotoxicity assay. Peripheral blood lymphocytes (PBLs) were incubated for 3 days with or without added IL-2. IL-2-activated PBLs showed significant cytotoxicity against autologous and allogeneic targets, while only low levels of tumor lysis occurred with unstimulated PBLs. These findings suggest the possible use of IL-2-activated lymphocytes in the adoptive immunotherapy of HNSCC patients.
Leess
F R
FR
Department of Surgery, University of California, Los Angeles School of Medicine.
Bredenkamp
J K
JK
Lichtenstein
A
A
Mickel
R A
RA
D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000276:immunology*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D014407:Tumor Cells, Cultured
D007376:Interleukin-2